TGTX Q3 2021 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+5242.1% YoY

Gross Profit

$2M85.6% margin

Operating Income

-$85M-4193.5% margin

Net Income

-$86M-4218.6% margin

EPS (Diluted)

$-0.65

QoQ Revenue Growth

+31.4%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$67M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$410M

Total Liabilities

$98M

Stockholders' Equity

$312M

Cash & Equivalents

$327M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$38,000	+5242.1%
Gross Profit	$2M	$38,000	+4473.7%
Operating Income	-$85M	-$86M	+0.7%
Net Income	-$86M	-$87M	+1.8%

Revenue Segments

Product revenue, net

$2M98%

License revenue

$38,0002%